VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2021 | Migraine symptom resolution occurs within an hour with eptinezumab administered during an attack

Jessica Ailani, MD, MedStar Georgetown University Hospital, Georgetown, Washington, DC, discusses an exploration of time to migraine symptom resolution in the RELIEF study (NCT04152083) of eptinezumab versus placebo, administered to patients during an acute attack of migraine. The earliest time points at which eptinezumab separated from placebo in rates of headache pain freedom, absence of most bothersome symptom (MBS), and absence of cardinal migraine symptoms was assessed. The analysis found that treatment with epitenzumab separated from placebo at 1 hour for headache pain freedom, absence of MBS, photophobia and phonophobia. Earliest separation for absence of nausea occurred at 0.5 hours. These findings indicate the rapid efficacy of eptinezumab administered during a migraine attack. This interview took place during the European Academy of Neurology 2021 congress.

Disclosures

Consulting: (Honoraria for independent consulting) Amgen, Abbvie, Biohaven, Eli Lilly and Company, Lundbeck, Teva, Impel, Satsuma, Theranica, Axsome, Neso, GlaxoSmithKline, Aeon, Medscape
Ownership of Stocks: CtrlM
Speakers Bureau: (Honoraria for promotional speaking) Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva
Editorial services: (Honoraria) Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, SELF (medical reviewer)
Clinical Trial Grants: (Fees to Institution) American Migraine Foundation, Allergan, Biohaven, Eli Lilly and Company, Satsuma, Zosano